Implications of Biological and Procedural Factors of 18-f... | NCT06626932

Studies
Implications of Biological and Procedural Factors of 18-f FDG Uptake by Normal Organs and Neoplastic Lesions

NCT06626932

Sponsor

mahenoor alaa eldeen naem

Status

Not yet recruiting

Last Update Posted

Oct 4, 2024Actual

Enrollment

259Estimated

Phase

Not provided

Conditions

Oncologic Diseases

Interventions

18 FDG (Fludeoxyglucose 18F)

Countries

Egypt

Protocol Section

Identification Module Status Module Sponsor/Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms/Interventions Module Outcomes Module Eligibility Module Contacts/Locations Module References Module IPD Sharing Statement Module

Results Section

Participant Flow Module Baseline Characteristics Module Outcome Measures Module Adverse Events Module More Info Module

Annotation Section

Annotation Module

Document Section

Large Document Module

Derived Section

Miscellaneous Info Module Condition Browse Module Intervention Browse Module

Protocol Section

Identification Module

NCT ID

Results Section

No data available

No data is available for this block.

Annotation Section

No data available

No data is available for this block.

Document Section

No data available

No data is available for this block.

Derived Section

Miscellaneous Info Module

Version Holder

Status Module

Record Verification Date

Sep 2024

Overall Recruitment Status or Expanded Access Status

Not yet recruiting

Last Known Status

Not provided

Delayed Posting

Not provided

Why Stopped

Not provided

Expanded Access Info

Start Date

Oct 2024Estimated

Primary Completion Date

Oct 2026Estimated

Completion Date

Nov 2026Estimated

First Submitted Date

Sep 27, 2024

First Submission Date that Met QC Criteria

Oct 2, 2024

First Posted Date

Oct 4, 2024Actual

Results Waived

Not provided

Results First Submitted Date

Not provided

Results First Submitted that Met QC Criteria

Not provided

Results First Posted Date

Not provided

Certification/Extension (aka Delayed Results) First Submitted Date

Not provided

Certification/Extension First Submitted that Passed QC Review

Not provided

Certification/Extension First Posted Date

Not provided

Last Update Submitted Date

Oct 2, 2024

Last Update Posted Date

Oct 4, 2024Actual

Oversight Module

Has Data Monitoring Committee (DMC)

Is FDA Regulated Drug

Is FDA Regulated Device

Is Unapproved Device

Not provided

Pediatric Postmarket Surveillance of a Device Product

Not provided

Product Exported from US

FDAAA801 Violation

Not provided

Description Module

Brief Summary

To evaluate implications of biological and procedural factors of 18-f FDG PET/CT uptake on normal organs and neoplastic lesions.

Detailed Description

18-f FDG is used on oncological patients undergoing PET/CT study at our nuclear medicine unit , its uptake by the tissues depends on glucose blood level and consumption then we evaluate the implications of biological and procedural factors on the uptake by normal organs and neoplastic lesions using standardized uptake values SUVmax , mean and peak.

Design Module

Study Type

Observational

Number of References to an Expanded Access Study

Not provided

Expanded Access Types

Not provided

Patient Registry

Target Follow-Up Duration

Not provided

Phases

Not provided

Interventional Study Design

Allocation

Not provided

Intervention Model

Biospecimen

No data available

No data is available for this block.

Enrollment

259Estimated

Name	Type	Description	Arm Group Labels	Other Names
18 FDG (Fludeoxyglucose 18F)	Radiation	18-f FDG

Outcomes Module

Primary Outcomes

Measure	Description	Time Frame
PET/CT scan on cancer patient will be performed to evaluate the biological and procedural factors of 18-f FDG uptake by multiple normal organs and neoplastic lesions using Standardized uptake values	SUV mean , suv peak and suv max	2 years

Secondary Outcomes

Not provided

Other Outcomes

Not provided

Eligibility Module

Eligibility Criteria

Inclusion Criteria:

cancer patients referred to nuclear medicine unit

Exclusion Criteria:

patients with increased FDG uptake associated with non malignant causes such as diffuse bone marrow FDG uptake or lung infection or patients with extensive metastasis in target organs

Accepts Healthy Volunteers

Sex

All

Sex/Gender Based

Not provided

Sex/Gender Description

Not provided

Minimum Age

1 Year

Maximum Age

90 Years

Standard Ages

ChildAdultOlder Adult

Study Population

all cancer patients

Sampling Method

Probability Sample

Contacts/Locations Module

Central Contacts

Name	Role	Phone	Extension	Email
Mahenoor Alaa Abouelouon, Master	Contact	201000488247		mahyswifty@gmail.com
nadia mohany mostafa, assistant professor	Contact	01125006468		drnadia1980@gmail.com

Overall Officials

Not provided

Locations

Facility	Status	City	State	ZIP	Country	Contacts
Faculty of Medicine		Asyut			Egypt

Intervention Browse Module

MeSH Terms

ID	Term
D019788	Fluorodeoxyglucose F18

Ancestor Terms

ID	Term
D003847	Deoxyglucose
D003837	Deoxy Sugars
D002241	Carbohydrates

Browse Leaves

Not provided

Browse Branches

Not provided